Personalising adherence-enhancing interventions using a smart inhaler in patients with COPD: an exploratory cost-effectiveness analysis.
Job Frank Martien van BovenBreda CushenImran SulaimanGarrett GreeneElaine MacHaleMatshediso C MokokaProf Frank DoyleRichard B ReillyKathleen BennettRichard W CostelloPublished in: NPJ primary care respiratory medicine (2018)
Four inhaler adherence clusters have been identified using the INCA audio device in COPD patients: (1) regular use/good technique, (2) regular use/frequent technique errors, (3) irregular use/good technique, and (4) irregular use/frequent technique errors. Their relationship with healthcare utilization and mortality was established, but the cost-effectiveness of adherence-enhancing interventions is unknown. In this exploratory study, we aimed to estimate the potential cost-effectiveness of reaching optimal adherence in the three suboptimal adherence clusters, i.e., a theoretical shift of clusters 2, 3, and 4 to cluster 1. Cost-effectiveness was estimated over a 5-year time horizon using the Irish healthcare payer perspective. We used a previously developed COPD health-economic model that was updated with INCA trial data and Irish national economic and epidemiological data. For each cluster, interventions would result in additional quality-adjusted life years gained at reasonable investment. Cost-effectiveness was most favorable in cluster 3, with possible cost savings of €845/annum/person.
Keyphrases
- healthcare
- chronic obstructive pulmonary disease
- lung function
- physical activity
- end stage renal disease
- glycemic control
- electronic health record
- chronic kidney disease
- ejection fraction
- patient safety
- quality improvement
- prognostic factors
- type diabetes
- clinical trial
- health information
- newly diagnosed
- cystic fibrosis
- emergency department
- primary care
- randomized controlled trial
- peritoneal dialysis
- cardiovascular events
- study protocol
- coronary artery disease
- machine learning
- adipose tissue
- metabolic syndrome
- phase iii
- weight loss
- placebo controlled